{"id":798178,"date":"2025-01-06T16:19:11","date_gmt":"2025-01-06T21:19:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"modified":"2025-01-06T16:19:11","modified_gmt":"2025-01-06T21:19:11","slug":"oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan.  06, 2025  (GLOBE NEWSWIRE) &#8212; ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. PT.<\/p>\n<p align=\"justify\">A live webcast of the company presentation will be available through the investor section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8-KLJbwvXW7u_ZXEPcUj0F-g4oV3XS5f8lPjf5DgdRf-xxe4RGfrgBehkTewordBtAQHEDFFVmnJEBi93dzgUn_eRXMXfu_iZfKQNDRbeos=\" rel=\"nofollow\" target=\"_blank\"><u>www.oricpharma.com<\/u><\/a>. A replay of the webcast will be available for 90 days following the event.<\/p>\n<p align=\"justify\">\n        <strong>About ORIC Pharmaceuticals, Inc. <\/strong><br \/>\n        <br \/>ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by\u00a0<em>Overcoming\u00a0Resistance\u00a0In\u00a0Cancer.\u00a0<\/em>ORIC\u2019s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers, and (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these two product candidates, ORIC<sup>\u00ae<\/sup> is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8-KLJbwvXW7u_ZXEPcUj0N7gVvSsKaaN73u-skVBH2rPvuG8AHW1Oqrf76s5b0C4jKCBoCd2H2_B3VgN2oKLm9naphI5dgdZd8winbqIYgz3e7caYunv9HT2Cbk9xbZDLgjU6cx8o7fG47zikr8PqjErN-E8FPEs6nULaKds27DRBa2kkIvX5tl7gPF7eDU-1T3okAasQLu_ssltORiVVGEypFJzXn_fUbP-svgS4yQvu_0EG52C8zt89EQXaOlvRf-cyb8yBoXVvHNqXIjMYw==\" rel=\"nofollow\" target=\"_blank\"><u>www.oricpharma.com<\/u><\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NL6-xYULBqXf7tSH1-FO4Lz7T9yfX6k84-RIEMaGQfCbdbTENClO4i9jUR51i4yPTEkRlYXj-iqu9cztzz9CyUGQ1mbGhGHV_qBhRNeE090jaDd8ce7aAIm2HAmZ9KoTP6kHZ9GXYYqUuQ6fYmmpLRcOZNINa5nz7gRMgPBxEfsjOw316CxajFTyEQjCjgMm3mKKqhiZOxngN3W9PcUIXQ==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a><u>\u00a0<\/u>or<u>\u00a0<\/u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L2lklCFu6rUEU07sodIGvbYqreHxXyJjeHCqyUlFuQaa_tUbkHNIyM2MInGTIWI-7O6Amrj6Srmzs4ugP4sDsJMAiJ7vyapxsHwFmT33FqZEGu0Nx7GCkH7l34fm0mu4gHORJYPir-yYudLP-PPUFTzLtPd_BtSVZ7N7haGU2fYZEyrANozRR0NCtTAltls-YIp2XOK86qMvIhmPQw1ycTEqsK7vw_iEYNZYA4Qm3MQDE5yylEXyn_R5O037a4IxWfOjttOPXRGxmq4bjIvHfQ==\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Dominic Piscitelli, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0Nk5fMyRf70gKL64Rv_MQ30vz49bemgTiAf6iiyL__m-Bn72h81PofrRwWtL4hnPOxfX32TGl5mgCN3ihBd3-A4ocXFxYZmgssELL046xS93Q83xbsCAj7mppWaNsS6wHYGv0uABUzKqqMeMHalOcA==\" rel=\"nofollow\" target=\"_blank\">dominic.piscitelli@oricpharma.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8dRL8NbeRXBpX-9c0XarbPXUqqFAHtbfEtdFHbB9FRq-IIGPMcINsSpVwbp4wk5D2EaWPV8TBmk54zNiRQAB261lA2R1j7W84D7HI-yoTUk=\" rel=\"nofollow\" target=\"_blank\">info@oricpharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzZlYmM4NjEtMzI1MS00MDBlLTk3ZWYtMjEyNWQ0NmU0OTU1LTEwOTI0NTY=\/tiny\/ORIC-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) &#8212; ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. PT. A live webcast of the company presentation will be available through the investor section of the company\u2019s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by\u00a0Overcoming\u00a0Resistance\u00a0In\u00a0Cancer.\u00a0ORIC\u2019s clinical stage product &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798178","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) &#8212; ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. PT. A live webcast of the company presentation will be available through the investor section of the company\u2019s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by\u00a0Overcoming\u00a0Resistance\u00a0In\u00a0Cancer.\u00a0ORIC\u2019s clinical stage product &hellip; Continue reading &quot;ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-06T21:19:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference\",\"datePublished\":\"2025-01-06T21:19:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":242,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU=\",\"datePublished\":\"2025-01-06T21:19:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) &#8212; ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. PT. A live webcast of the company presentation will be available through the investor section of the company\u2019s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by\u00a0Overcoming\u00a0Resistance\u00a0In\u00a0Cancer.\u00a0ORIC\u2019s clinical stage product &hellip; Continue reading \"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-06T21:19:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference","datePublished":"2025-01-06T21:19:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"wordCount":242,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","name":"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU=","datePublished":"2025-01-06T21:19:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM1MyM2NjY5MzA3IzIwODA4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ORIC\u00ae Pharmaceuticals to Present at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798178"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798178\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}